Budget Impact of Memantine for Alzheimer's Patient in the United States
Author(s)
Almutairi R1, Sanogo V2, Diaby K3
1MCPHS UNIVERSITY, Boston, MA, USA, 2Northcentral University, GAINESVILLE, FL, USA, 3Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA
Presentation Documents
Background: 6.7 million Americans 65 and older will have Alzheimer's by 2023. 73% of the population is 75 years or older. The projected frequency of AD worldwide in 2050 is 12.7 million. Acetylcholinesterase inhibitors (AChEIs) including donepezil, galantamine, and rivastigmine are used to treat mild and severe AD. Alzheimer's and other dementias will cost the US $345 billion in 2023, of which $222 billion will come from Medicare and Medicaid.
OBJECTIVES:
Determine the effect of Memantine on total healthcare cost for treating ADRD in the US.METHODS:
A budget impact model was created to calculate the financial ramifications of using Memantine to treat Alzheimer's patients. A cohort of 1 million was chosen and modeled over 3 years in both with and without Memantine scenarios. Inputs included market share, costs, length of therapy, and patient compliance projections. The difference in annual costs and PMPM/per treated member was used to determine the budget impact with deterministic sensitivity analyses to examine how changes in parameters affected the model results.RESULTS:
The estimated budget impact of introducing Memantine for treating eligible patients with Alzheimer's disease in the US from a health plan of one million members over three years is $5,789,541, with an incremental PMPM cost of $0.48 and a PTMPM cost of $42.81. Sensitivity analysis suggests a modest increase in budget, mainly due to improved compliance with treatment regimens.CONCLUSIONS:
Memantine, a treatment option for adults with Alzheimer's, had minimal impact on US health plan budgets with potential for improved patient adherence through six annual doses.Conference/Value in Health Info
2023-11, ISPOR Europe 2023, Copenhagen, Denmark
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
EE350
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Drugs, Neurological Disorders